Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996005166 - SUBSTITUTED AMINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE SAME

Publication Number WO/1996/005166
Publication Date 22.02.1996
International Application No. PCT/JP1995/001587
International Filing Date 09.08.1995
Chapter 2 Demand Filed 10.11.1995
IPC
C07C 237/44 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
237Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
28having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
44having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
C07D 209/42 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02condensed with one carbocyclic ring
04Indoles; Hydrogenated indoles
30with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/58 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
211Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
06having no double bonds between ring members or between ring members and non-ring members
36with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
56Nitrogen atoms
58attached in position 4
C07D 213/82 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
04having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
60with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
81Amides; Imides
82in position 3
C07D 215/54 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
215Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
02having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
16with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
54attached in position 3
C07D 235/06 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
235Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
02condensed with carbocyclic rings or ring systems
04Benzimidazoles; Hydrogenated benzimidazoles
06with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
CPC
C07C 237/44
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
237Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
28having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
44having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
C07C 2601/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
2601Systems containing only non-condensed rings
06with a five-membered ring
08the ring being saturated
C07C 2601/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
2601Systems containing only non-condensed rings
12with a six-membered ring
14The ring being saturated
C07C 2601/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
2601Systems containing only non-condensed rings
18with a ring being at least seven-membered
C07D 209/42
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02condensed with one carbocyclic ring
04Indoles; Hydrogenated indoles
30with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/58
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
211Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
06having no double bonds between ring members or between ring members and non-ring members
36with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
56Nitrogen atoms
58attached in position 4
Applicants
  • YAMANOUCHI PHARMACEUTICAL CO., LTD. [JP]/[JP] (AllExceptUS)
  • SUZUKI, Takeshi [JP]/[JP] (UsOnly)
  • IMANISHI, Naoki [JP]/[JP] (UsOnly)
  • ITAHANA, Hirotsune [JP]/[JP] (UsOnly)
  • WATANUKI, Susumu [JP]/[JP] (UsOnly)
  • KAMATO, Takeshi [JP]/[JP] (UsOnly)
  • MIYATA, Keiji [JP]/[JP] (UsOnly)
  • OHTA, Mitsuaki [JP]/[JP] (UsOnly)
Inventors
  • SUZUKI, Takeshi
  • IMANISHI, Naoki
  • ITAHANA, Hirotsune
  • WATANUKI, Susumu
  • KAMATO, Takeshi
  • MIYATA, Keiji
  • OHTA, Mitsuaki
Agents
  • NAGAI, Shozo
Priority Data
6/18925211.08.1994JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) SUBSTITUTED AMINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE SAME
(FR) DERIVE D'AMINE SUBSTITUE ET COMPOSITION MEDICAMENTEUSE LE CONTENANT
Abstract
(EN)
A substituted amine derivative represented by general formula (I), having an agonistic activity on 5-HT4 receptors, and useful as a 5-HT4 receptor agonist for preventing and/or treating diseases accompanied with the insufficiency of such an agonistic activity, such as central nervous system disorder or digestive tract movement disorder, a pharmaceutically acceptable salt thereof, a medicinal composition containing the same, and an intermediate represented by general formula (IIIa) wherein ring A represents a benzene ring, a heterocycle containing N, S or O, etc.; X represents -CONR5-, etc.; R1 and R2 represent each hydrogen or lower alkyl; ring B represents a cycloalkane ring or a heterocycle containing N, S or O; and R3 and R4 represent each hydrogen or lower alkyl, or R3, R4 and the adjacent nitrogen atom are combined together to represent a heterocycle.
(FR)
Représenté par la formule générale (I), un dérivé d'amine substitué présente une activité agoniste par rapport aux récepteurs 5-HT4 et est utile comme agoniste du récepteur 5-HT4 pour prévenir et/ou traiter des maladies accompagnées par une insuffisance d'une telle activité agoniste, telles que des troubles du système nerveux central ou des contractions du tube digestif. On décrit aussi un de ses sels pharmacologiquement acceptables, une composition médicamenteuse le contenant et un intermédiaire représenté par la formule générale (IIIa), dans laquelle le cycle A est un cycle benzène, un hétérocycle contenant N, S ou O, etc.; X représente -CONR5-, etc.; R1 et R2 représentent chacun hydrogène ou alkyle inférieur; le cycle B est un cycle cycloalcane ou un hétérocycle contenant N, S ou O; et R3 et R4 représentent chacun hydrogène ou alkyle inférieur, ou bien R3, R4 et l'atome d'azote adjacent se combinent en un hétérocyle.
Also published as
Latest bibliographic data on file with the International Bureau